Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Subscribe To Our Newsletter & Stay Updated
